![]() ![]() Hitesh Sharma for access to cIEF system for this investigation. The developed protocol here is a valuable tool to identify high-yield scalable refolding conditions for multi-domain proteins involving inter-domain disulfide bonds. The amino acid sequence for the disulfide-linked peptide was mapped using collision-induced dissociation (CID) to confirm the formation of inter-chain disulfide bonds between Cys7-Cys7 and Cys10-Cys10 similarly for intra-chain disulfide bonds between Cys42-Cys102, and Cys148-Cys206. The formation of native peptibody structure was examined using various orthogonal analytical tools to study the protein's primary, secondary, and tertiary structure. Under optimum refolding conditions, the maximum refolding yield of 57.0 ± 1.5 % and a purity of over 79.73 ± 3.4 % were achieved at 25-fold dilution, 15 ☌ temperature, 6 h residence time with 6 mM and 10 mM of cysteine and DTT, respectively. Effect of various critical process parameters like fold dilution, temperature, residence time, and Cysteine: DTT ratio was studied using a central composite based design of experiment strategy to achieve a maximum refolding yield of selected peptibody. A plug flow tubular reactor was connected in series with capture step affinity chromatography to achieve simultaneous in-vitro refolding and capture step purification of recombinant Romiplostim. Recombinant Romiplostim was selected as a model protein for the study. This study is focused on developing a chromatography-assisted in-vitro refolding platform to produce the biologically active, native form of recombinant peptibody. Is there a possibility to use chromatography for in-vitro refolding of multi-domain proteins involving inter-chain and intra-chain disulfide bond formation? #plasticfreeoceans #plasticwastemanagement #bioplastics Responsible use of plastic is what we need to promote. Widespread availability of products made from recycled plastics encourages their usageĥ. Understanding safe-grade plastics and proper disposal methods are crucial to tackling the plastic problem. ![]() Recycling plastic reduces the demand for raw materials and cuts down costsĤ. Food-grade plastics are indispensable in the CPG industry to ensure product safety and durabilityĢ. Producing 100% recyclable plastics alleviates the burden on industries that cannot switch to alternatives overnightģ. The solution to the plastic hazard lies in rethinking the entire lifecycle of plastic, encompassing its production, usage, disposal, and recycling processes. Why does this continue to happen, even when the call to eliminate plastic grows louder? Notice the food packets and bottles buried beneath the sand and thrown behind the trees. Take a stroll on the beaches or hike up the mountains. The tenacity becomes evident when we consider the massive amounts that we discard daily, with a good share of it ending up in landfills, and tragically, finding its way to the vast oceans. The demand generated for plastic in India in the financial year 2021-2022 was approximately 15 million tons. But, even with our best intentions, plastic still manages to sneak into our lives in unexpected ways, like an old friend. In the long battle of eliminating synthetic polymers, you and I have done our part in freeing our office spaces and homes of plastic. Plastic to many of us is an old friend who just won't leave. #JLLLifeSciences #LifeSciencesTrends #biopharma The recent uptick in job postings is a leading indicator that growth is mounting, and this could translate into the need for additional lab space in the future. ▪️ After a drop-off in life sciences tenant touring activity in 2022, tenant demand plateaued across the first half of 2023. ▪️ Johnson & Johnson, Sanofi, Icon, Pfizer and Takeda have posted the most job openings in the same time period, respectively. ▪️ Cumulatively in the first half of this year, Massachusetts saw the most unique biopharma job postings with 17,732, quickly followed by California with 17,316. Companies have had the time to make plans around the reality of the looming broader macroeconomic environment which is reflected in the uptick of job openings. Amid economic uncertainties we saw early-stage companies struggle in a difficult funding environment and larger established companies operate with more caution which led to the decline in job openings. ▪️ Previously, job postings had significantly dropped off through the second half of 2022 and into 2023. Year over year, June postings were up 11%. June 2023 had the 6th highest number of biopharma job openings in any month on record and was on par with the peaks seen in 2022. ▪️ Since March of this year, appetite for life sciences talent has begun to pick up steam. Here are the key takeaways from our latest life sciences research ⬇️ Biopharma job openings picked up substantially through Q2 2023.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |